(NASDAQ: INDV) Indivior's forecast annual revenue growth rate of -0.68% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.69%.
Indivior's revenue in 2025 is $1,181,000,000.On average, 9 Wall Street analysts forecast INDV's revenue for 2025 to be $149,949,530,297, with the lowest INDV revenue forecast at $137,214,432,803, and the highest INDV revenue forecast at $156,691,640,735. On average, 9 Wall Street analysts forecast INDV's revenue for 2026 to be $141,958,880,889, with the lowest INDV revenue forecast at $126,601,851,558, and the highest INDV revenue forecast at $157,565,618,014.
In 2027, INDV is forecast to generate $146,828,182,872 in revenue, with the lowest revenue forecast at $130,971,737,953 and the highest revenue forecast at $166,430,244,701.